GENFIT and EVerZom have initiated a research collaboration to explore EViv, an innovative exosome-based regenerative therapy for Acute-On-Chronic Liver Failure (ACLF), with plans to conduct exploratory studies and potentially advance into clinical development within 18 months.

GENFIT and EVerZom have partnered to explore a novel regenerative medicine approach using exosomes for treating Acute on Chronic Liver Failure (ACLF), with GENFIT gaining exclusive rights to license the experimental drug EViv if preclinical studies show promising results.

GENFIT has presented promising preclinical data on NTZ/G1090N for treating Acute-on-Chronic Liver Failure (ACLF), demonstrating significant effects on systemic inflammation and organ function in disease models. A Phase 1 study in healthy volunteers is ongoing, with safety data and initial efficacy markers expected by late 2025.

GENFIT presented preclinical data on nitazoxanide (NTZ) and investigational drug G1090N, demonstrating potential efficacy in treating Acute-on-Chronic Liver Failure (ACLF) by reducing systemic inflammation and improving organ function. Safety data from Phase 1 trials in healthy volunteers is expected by year-end 2025.

GENFIT has signed Put Option Agreements with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs. The company has convened a general meeting of the 2025 OCEANEs holders on March 10, 2025 to approve the amendment of the terms and conditions of the 2025 OCEANEs and the closing of a royalty financing transaction.